Highlights: - Successful production of 5,000 x RECCE® 327 (R327) doses per week under Good Manufacturing Practises (GMP) campaign. - R327 manufactured under GMP standards in support of present Phase I, Phase II and anticipated Registrational Phase III clinical trials, demonstrating compliance with guidelines set by regulatory authorities, such as the U.S. Food and Drug Administration. Sydney Australia, 16 April 2024: Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (the Company) developing a New Class of ...
[ more ]
